Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Black Diamond reports Phase 2 silevertinib data, plans FDA meeting on pivotal pathAug 5Quarterly updateBlack Diamond Therapeutics, Inc.silevertinib